Aeluma, Inc. filings document the reporting record of a Nasdaq-listed emerging growth semiconductor company developing scalable photonic and electronic technologies. Its periodic and current reports cover financial results, quarterly reporting, Regulation FD materials, investor presentations and public-company disclosure controls.
The company’s SEC filings also describe capital-structure activity involving common stock, shelf registration, underwriting agreements and sales-agreement arrangements for registered equity issuance. Governance disclosures include annual meeting voting results, director elections and shareholder approvals, while other current reports address material definitive agreements and Rule 10b5-1 trading-plan disclosures.
Aeluma, Inc. Chief Executive Officer Jonathan Klamkin reported open-market sales of a total of 50,000 shares of Aeluma common stock on March 4, 2026, executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025.
The transactions consisted of 28,206 shares sold at a weighted average price of $17.7746 per share, with individual sale prices ranging from $17.11 to $18.10, and 21,794 shares sold at a weighted average price of $18.4110 per share, with prices ranging from $18.11 to $19.03.
Following these sales, Klamkin directly owned 1,429,398 shares of Aeluma common stock.
ENSLEY CRAIG H reported acquisition or exercise transactions in this Form 4 filing.
Aeluma, Inc. director Craig H. Ensley reported an equity award of 10,633 shares of common stock in the form of restricted stock units at a stated price of $0.00 per share. After this grant, he holds 27,300 shares of common stock. The units are scheduled to vest in stages: about 1/12 on December 31, 2025, 1/4 on March 31, June 30, and September 30, 2026, and 1/6 on November 30, 2026.
Paglia John Kenneth reported acquisition or exercise transactions in this Form 4 filing.
Aeluma, Inc. director John Kenneth Paglia reported receiving a grant of 10,861 shares of common stock in the form of restricted stock units at a stated price of $0 per share. Following this award, he holds 23,361 shares directly. The units are scheduled to vest over time: about 1/12 on December 31, 2025, 1/4 each on March 31, June 30, and September 30, 2026, and 1/6 on November 30, 2026.
Aeluma, Inc. director Byron Michael reported receiving equity-based compensation in the form of common stock and stock options. He was granted 13,343 shares of common stock as restricted stock units that are scheduled to vest over several dates through November 30, 2026. The vesting schedule covers approximately 1/12 of the shares on December 31, 2025, 1/4 of the shares on March 31, June 30, and September 30, 2026, and 1/6 of the shares on November 30, 2026. He also acquired stock options for 3,653 shares that are fully vested as of the grant, giving him the right to buy additional common stock.
Denbaars Steven reported acquisition or exercise transactions in this Form 4 filing.
Aeluma, Inc. director Steven Denbaars reported an equity award of 10,121 shares of common stock in the form of restricted stock units at a stated price of $0.00 per share. Following this grant, his reported direct holdings total 395,209 shares of common stock.
The restricted stock units are scheduled to vest over several dates: approximately one-twelfth of the shares on December 31, 2025, one-quarter of the shares on March 31, June 30, and September 30, 2026, and the remaining one-sixth on November 30, 2026.
Aeluma, Inc. director Steven Denbaars reported selling a total of 25,000 shares of common stock in two open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on November 20, 2025. He sold 12,500 shares on February 25, 2026 at a weighted average price of $17.5813 per share and 12,500 shares on February 26, 2026 at a weighted average price of $15.8475 per share, with actual sale prices on each day spanning disclosed ranges. After these sales, he continues to hold 385,088 shares directly.
Aeluma, Inc. (ALMU) received an updated large‑holder report from investor Mark N. Tompkins, disclosing a significant passive stake in the company. He reports beneficial ownership of 2,024,988 shares of Aeluma common stock, representing 11.34% of the outstanding shares as of December 31, 2025.
The percentage is based on 17,857,863 Aeluma common shares outstanding as of November 21, 2025, as cited from the company’s proxy statement. Tompkins has sole voting and sole dispositive power over all reported shares and certifies the holdings are not for the purpose of changing or influencing control of Aeluma.
Aeluma, Inc. reported revenue of $2.7 million for the six months ended December 31, 2025, up from $2.1 million a year earlier, mainly from U.S. government contracts. Operating expenses rose sharply to $6.3 million, driven by higher materials costs and expanding headcount, leading to a net loss of $3.3 million, slightly better than the prior period’s $3.6 million loss.
The company strengthened its balance sheet with two underwritten equity offerings in March and September 2025, providing net proceeds of $12.6 million and $23.4 million. Cash, cash equivalents and a certificate of deposit increased to $38.6 million, and management states that prior substantial doubt about its ability to continue as a going concern has been alleviated for at least the next twelve months. However, disclosure controls and procedures were deemed not effective due to limited finance staffing, and remediation efforts, including hiring a new chief financial officer and adding accounting resources, are underway.